Value of external validation of REAL-B score in predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients treated by antiviral therapy

Xue WU; Weike CHU; Hui ZHOU; Bin NIU; Peng ZHANG; Jing FENG; Yuqiang MI; Ping LI

doi:10.3969/j.issn.1001-5256.2022.08.010

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1768-1773

PDF( 2834 KB)

Value of external validation of REAL-B score in predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients treated by antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2022.08.010

Xue WU¹,
Weike CHU¹,
Hui ZHOU¹,
Bin NIU¹,
Peng ZHANG¹,
Jing FENG¹,
Yuqiang MI²,
Ping LI^{2
,
,
,}

1.
Clinical College of The Second People's Hospital, Tianjin Medical University, Tianjin 300070, China
2.
Tianjin Hepatopathy Research Institute, Tianjin Second People's Hospital, Tianjin 300192, China

Research funding:

Wang Bao'en Liver Fibrosis Research Fund of China Hepatitis Prevention foundation (2021038)

More Information

Corresponding author: LI Ping, tjlplxg@163.com(ORCID: 0000-0001-9930-6429)
Received Date: 2021-12-19
Accepted Date: 2022-01-20
Published Date: 2022-08-20

Abstract

Abstract

Objective To investigate the value of the hepatocellular carcinoma (HCC) risk model REAL-B score in predicting the risk of HCC in chronic hepatitis B (CHB) patients receiving antiviral therapy in comparison with mPAGE-B, aMAP and PAGE-B scores. Methods A retrospective analysis was performed for the clinical data of 1160 CHB patients who received entecavir or tenofovir treatment for more than 1 year from January 2013 to December 2015 in Tianjin Second Peolple's Hospital, and the events of HCC were recorded. The area under the ROC curve (AUC) was used to evaluate the value of REAL-B, mPAGE-B, aMAP, and PAGE-B scores in predicting HCC. The Kaplan-Meier method was used to evaluate the cumulative incidence rate of HCC at different time points, and the log-rank test was used to compare the incidence rate of HCC between the groups with different scores. The independent samples t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups. Results Among the 1160 CHB patients, 108 (9.8%) progressed to HCC within a median follow-up time of 5.3 (5.0-6.3) years. REAL-B score had an AUC of 0.848 (95% confidence interval [CI]: 0.816-0.880) in predicting the onset of HCC within 5 years, followed by aMAP score (AUC=0.823, 95% CI: 0.786-0.860), mPAGE-B score (AUC=0.822, 95%CI: 0.788-0.857), and PAGE-B scores (AUC=0.780, 95%CI: 0.736-0.824). The 5-year cumulative incidence rate of HCC was 0.8% in the low-risk group (with a REAL-B score of 0-3 points), which was significantly lower than the incidence rate of 11.8% in the medium-risk group (with a REAL-B score of 4-7 points) and 35.6% with the high-risk group (with a REAL-B score of 8-13 points) (P < 0.05). In the low-risk group, REAL-B score had a negative predictive value of 100% and 99.67%, respectively, in predicting HCC within 3 and 5 years. Conclusion REAL-B score accurately predicts the risk of HCC in CHB patients receiving antiviral therapy, with a better predictive value than the other risk models within 3 years of antiviral therapy.
- Hepatitis B, Chronic,
- Carcinoma, Hepatocellular,
- Risk Factors

FullText(HTML)

References(22)

References

[1]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[2]	BOCKMANN JH, KOHSAR M, MURRAY JM, et al. High rates of liver cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients with metabolic and cardiovascular comorbidities[J]. Microorganisms, 2021, 9(5): 968. DOI: 10.3390/microorganisms9050968.
[3]	SINGAL AK, SALAMEH H, KUO YF, et al. Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2013, 38(2): 98-106. DOI: 10.1111/apt.12344.
[4]	CHEN BW, ZHU XJ, ZHANG X, et al. Influence of virologic response on disease progression in patients with compensated hepatitis B cirrhosis[J]. J Clin Hepatol, 2021, 37(8): 1811-1816. DOI: 10.3969/j.issn.1001-5256.2021.08.014. 陈博武, 朱晓骏, 张鑫, 等. 病毒学应答状态对代偿期乙型肝炎肝硬化患者疾病进展的影响[J]. 临床肝胆病杂志, 2021, 37(8): 1811-1816. DOI: 10.3969/j.issn.1001-5256.2021.08.014.
[5]	KIM SU, SEO YS, LEE HA, et al. Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis B: A multicenter study[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(4): 832-837. DOI: 10.1158/1055-9965.EPI-19-0614.
[6]	PAPATHEODORIDIS GV, DALEKOS GN, IDILMAN R, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020, 73(5): 1037-1045. DOI: 10.1016/j.jhep.2020.06.011.
[7]	SOU FM, HU TH, HUNG CH, et al. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients[J]. Hepatol Int, 2020, 14(4): 513-520. DOI: 10.1007/s12072-020-10031-3.
[8]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[9]	European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma[J]. Eur J Cancer, 2012, 48(5): 599-641. DOI: 10.1016/j.ejca.2011.12.021.
[10]	LEE HW, YOO EJ, KIM BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy[J]. Am J Gastroenterol, 2014, 109(8): 1241-1249. DOI: 10.1038/ajg.2014.157.
[11]	PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64(4): 800-806. DOI: 10.1016/j.jhep.2015.11.035.
[12]	FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73(6): 1368-1378. DOI: 10.1016/j.jhep.2020.07.025.
[13]	KIM JH, KIM YD, LEE M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol, 2018, 69(5): 1066-1073. DOI: 10.1016/j.jhep.2018.07.018.
[14]	HSU YC, YIP TC, HO HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B[J]. J Hepatol, 2018, 69(2): 278-285. DOI: 10.1016/j.jhep.2018.02.032.
[15]	YANG HI, YEH ML, WONG GL, et al. Real-world effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis, 2020, 221(3): 389-399. DOI: 10.1093/infdis/jiz477.
[16]	Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004. 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
[17]	ZHOU J, SUN H, WANG Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J]. Liver Cancer, 2020, 9(6): 682-720. DOI: 10.1159/000509424.
[18]	LIU L, SHI K, ZHANG Q, et al. Risk factors for hepatocellular carcinoma in patients with chronic hepatitis B[J]. J Clin Hepatol, 2021, 37(7): 1591-1593. DOI: 10.3969/j.issn.1001-5256.2021.07.022. 刘龙, 时克, 张群, 等. 慢性乙型肝炎患者发生肝细胞癌的危险因素分析[J]. 临床肝胆病杂志, 2021, 37(7): 1589-1593. DOI: 10.3969/j.issn.1001-5256.2021.07.022.
[19]	LEE HW, KIM SU, PARK JY, et al. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy[J]. Liver Int, 2019, 39(9): 1624-1630. DOI: 10.1111/liv.14129.
[20]	KIM MN, HWANG SG, RIM KS, et al. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir[J]. Liver Int, 2017, 37(12): 1788-1795. DOI: 10.1111/liv.13450.
[21]	PAPATHEODORIDIS GV, SYPSA V, DALEKOS GN, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020, 72(6): 1088-1096. DOI: 10.1016/j.jhep.2020.01.007.
[22]	WONG GL, CHAN HL, WONG CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J]. J Hepatol, 2014, 60(2): 339-345. DOI: 10.1016/j.jhep.2013.09.029.

Relative Articles

[1]	Fang WANG, Jianhua LU, Yonggang LIU, Xinyu ZHANG, Huimin YAN. Expression and significance of immune cells in patients with hepatitis B virus-related acute-on-chronic pre-liver failure[J]. Journal of Clinical Hepatology, 2023, 39(1): 77-82. doi: 10.3969/j.issn.1001-5256.2023.01.012
[2]	Kuan LI, Huibin NING, Huiming JIN, Zhen PENG, Jia SHANG. Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1819-1824. doi: 10.3969/j.issn.1001-5256.2023.08.009
[3]	Yifei GUO, Jiming ZHANG. Influencing factors for the functional cure of chronic hepatitis B and related mechanism[J]. Journal of Clinical Hepatology, 2022, 38(8): 1721-1725. doi: 10.3969/j.issn.1001-5256.2022.08.004
[4]	Zixiang GAO, Zhongliang SHEN, Jing LIU, Youhua XIE. Research advances in cytokines in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(8): 1710-1715. doi: 10.3969/j.issn.1001-5256.2022.08.002
[5]	Tingting ZHANG, Jue ZHAO, Yan YANG, Yaojie KANG, Xuan WANG. Type 1 diabetes mellitus due to pegylated interferon treatment of chronic hepatitis B: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1905-1906. doi: 10.3969/j.issn.1001-5256.2021.08.031
[6]	Xiaofei YANG, Linxu WANG, Changxing HUANG, Jie DONG, Haifeng HU, Zhanhu BI, Jianqi LIAN, Ye ZHANG. Mechanism of gamma-chain cytokines in regulating the expression of T-cell immunoglobulin and mucin domain-containing molecule 3 in CD8⁺ T cells of chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2021, 37(5): 1059-1064. doi: 10.3969/j.issn.1001-5256.2021.05.017
[7]	Limin WANG, Shuhong LIU, Shishu ZHU, Yi DONG, Zhiqiang XU, Fuchuan WANG, Jianguo YAN, Pu WANG, Aiqin LI, Lili CAO, Pan ZHAO, Min ZHANG. Association of the expression of HBsAg and HBcAg in liver tissue with antiviral response in children with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(1): 46-50. doi: 10.3969/j.issn.1001-5256.2021.01.010
[8]	Zhen PENG, Huiming JIN, Huibin NING, Kuan LI, Jia SHANG. Value of lymphocyte subset testing in predicting HBsAg decline in chronic hepatitis B patients receiving antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(9): 2071-2074. doi: 10.3969/j.issn.1001-5256.2021.09.014
[9]	Chen Xi, Zhao WenJing, Sun Yan, Yin HaiYan. Value of baseline HBsAg quantification in predicting the clinical effect of pegylated interferon α-2b in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(8): 1723-1726. doi: 10.3969/j.issn.1001-5256.2020.08.009
[11]	Peng JianPing, Sun KeWei, Yin SiHan, Wu YuNan. Effects of hepatitis B virus on the expression of Toll-like receptor 9,interferon regulatory factor-7,and interferon-α in plasmacytoid dendritic cells in the umbilical cord blood of healthy parturients[J]. Journal of Clinical Hepatology, 2016, 32(5): 894-898. doi: 10.3969/j.issn.1001-5256.2016.05.016
[12]	Yin SiHan, Liu Peng, Zhang Tao, Sun KeWei. Analysis of TCM deficiency and excess attributes in patients with HBV- related acute- on- chronic liver failure based on phenotype of dendritic cells and function of T lymphocytes[J]. Journal of Clinical Hepatology, 2016, 32(4): 663-668. doi: 10.3969/j.issn.1001-5256.2016.04.010
[13]	Jia Lin, Li Juan, Zhu YueKe, Zhao Juan, Liu HaiXia, Duan ZhongHui, Ren MeiXin, Meng QingHua. Count of peripheral blood dendritic cells and its clinical significance in patients with acute-on-chronic hepatitis B liver failure[J]. Journal of Clinical Hepatology, 2015, 31(5): 711-715. doi: 10.3969/j.issn.1001-5256.2015.05.019
[14]	Peng JianPing, Sun KeWei, Wu YuNan, Zhang QianQian. Programmed cell death 1 expression on HBV-specific CTLs induced by dendritic cells in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(12): 926-929.
[15]	Jiang Na, Pan Lei, Li Yuan, Zhang SuMei, Zhang Ying, Ma Li, Zhou Yun, Guo YaLing, Jia ZhanSheng. Antiviral treatment-induced phenotype changes in dendritic cells of peripheral blood from chronic HCV patients[J]. Journal of Clinical Hepatology, 2012, 28(6): 446-449+455.
[16]	Shi QingFeng, Zhang YingXin, Song JiKui, Yuan JianGuo, Li QingFang, Zhao HongKui, Ceng WeiQun, Chen Min. Effect of prostaglandin E1 on the dendritic cells maturation and the activity of CD4+/CD8+ T cells in chronic severe hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(3): 212-215.
[17]	Zhou Yun, Li Duan, Chen Lin, Zhao FuTao, Ma Li, Wang Hong, Pan Lei, Jia ZhanSheng. The construction of HCV multi-CTL epitopes dendritic cell vaccine and its effect of stimulating T cell response in vitro[J]. Journal of Clinical Hepatology, 2011, 27(1): 40-44.
[18]	Zou XiaoJing, Jiang XueQiang, Tian DeYing. Role of DC-SIGN on the maturation and activation of dendritic cells in chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2011, 27(2): 145-147+153.
[19]	Feng XiaoXia, Wang Lei, Xing LianJun, Liang HaiLin, Nie YuanXia. The function of dendritic cell in chronic hepatitis B patients with deficiency of kidney based on traditional chinese medicine syndrome differentiation intervention[J]. Journal of Clinical Hepatology, 2010, 26(6): 638-640.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (741) PDF downloads(78)

Value of external validation of REAL-B score in predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients treated by antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2022.08.010

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Value of external validation of REAL-B score in predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients treated by antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2022.08.010

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content